For patients with major depressive disorder (MDD)

Patient Information

First name:

Prior Authorization and Re-authorization Checklist

Middle initial:

This checklist is a guide provided by AbbVie that can help you complete the patient's required prior authorization (PA) form. It (1) may include certain PA criteria which are not necessary for a specific payer and (2) may not include all necessary PA requirements for a specific payer.

Last name:

Requested drug:		Date:	Patient 18 years of age or older			
Physician name:		Specialty:				
☐ Initial Authorization Request	Re-authorization (use only if a PA has be	een previously approved for the reques	ited drug)			
ICD-10-CM Diagnostic Codes	for Major Depressive Disorder¹ (check only one)				
☐ F33: Major depressive disorder, recurrent		☐ F33.2: Major depressive disorder, recurrent severe without psychotic features				
☐ F33.0: Major depressive disorder, recurrent, mild		☐ F33.3: Major depressive disorder, recurrent, severe with psychotic symptoms				
☐ F33.1: Major depressive disorder, recurrent, moderate		☐ F33.9: Major depressive disorder, recurrent, unspecified				
	tory for Major Depressiv					
Drug Class Prescribed	Drug Name	Dose Duration	Outcome			
☐ SNRIs ☐ SSRIs ☐ NDRI ☐ Atypical antipsychotic	ls		□ Contraindicated □ Failed □ Intolerant □ Suboptimal			
☐ SNRIs ☐ SSRIs ☐ NDRI ☐ Atypical antipsychotic	s		☐ Contraindicated ☐ Failed ☐ Intolerant ☐ Suboptimal			
□ SNRIs □ SSRIs □ NDRI □ Atypical antipsychotic	ls		☐ Contraindicated ☐ Failed ☐ Intolerant ☐ Suboptimal			
Will the patient continue to use any of the al ☐ No ☐ Yes – If yes, please list drug nam	pove drugs in combination with the requested	d medication?				
☐ No ☐ Tes = II yes, please list drug harr	10(0)					
Drug Class Examples Listed below are examples of the drug classes used for MDD. This is not a comprehensive list. Some medications listed below are not approved for MDD.						
Serotonin norepinephrine reuptake inhibitors (SNRIs)	Selective serotonin reuptake inhibitors (SSRIs)	Norepinephrine-dopamine reuptake inhibitors (NDRIs)	Atypical antipsychotics			
CYMBALTA® (duloxetine)	CELEXA® (citalopram)	WELLBUTRIN® (bupropion)	ABILIFY® (aripiprazole)			
EFFEXOR® (venlafaxine)	LEXAPRO® (escitalopram)	REXULTI® (brexpiprazole				
FETZIMA® (levomilnacipran)	LUVOX® (fluvoxamine)		SEROQUEL® (quetiapine)			
PRISTIQ® (desvenlafaxine)	PAXIL® (paroxetine)					
	PROZAC® (fluoxetine)					
	VIIBRYD® (vilazodone)					
	ZOLOFT® (sertraline)					
Are there any risk factors that would preven	t the patient from being prescribed any of the	above therapies?				
☐ No ☐ Yes – If yes, please list risk factor	'S:					
Additional relevant information:						

DOB:

For patients with bipolar I disorder and/or schizophrenia

Middle initial:

Patient Information

First name:

Prior Authorization and Re-authorization Checklist (continued)

This checklist is a guide provided by AbbVie that can help you complete the patient's required prior authorization (PA) form. It (1) may include certain PA criteria which are not necessary for a specific payer and (2) may not include all necessary PA requirements for a specific payer.

Last name:

DOB:

equested drug:		Date:	Date:		Patient 18 years of age or older		
Physician name:		Specialt	Specialty:				
☐ Initial Authorization Request	Re-authorization (use only if a PA ha	as been previously appro	ved for the requ	uested drug)			
ICD-10-CM Diagnostic Codes	for Bipolar Disorder ¹ (check o	only one)					
☐ F31: Bipolar disorder	☐ F31.6: Bipolar disc	☐ F31.6: Bipolar disorder, current episode mixed					
☐ F31.9: Bipolar disorder, unspecified		☐ F31.3: Bipolar disc	☐ F31.3: Bipolar disorder, current episode depressed, mild or moderate severity				
☐ F31.1: Bipolar disorder, current episor	☐ F31.4: Bipolar disorder, current episode depressed, severe, without psychotic features						
☐ F31.2: Bipolar disorder, current episo	ode manic severe with psychotic features	6					
ICD-10-CM Diagnostic Codes	for Schizophrenia¹ (check onl	y one)					
☐ F20: Schizophrenia	☐ F20.8: Other schiz	☐ F20.8: Other schizophrenia					
☐ F20.3: Undifferentiated schizophrenia	☐ F20.9: Schizophre	☐ F20.9: Schizophrenia, unspecified					
☐ F20.5: Residual schizophrenia							
Patient Medication His	tory for Bipolar Disor	der or Schizop	hrenia				
Drug Name	Dose	Duration	on	Outcome			
				☐ Contraindicated ☐ Intolerant	☐ Failed ☐ Suboptimal		
				☐ Contraindicated ☐ Intolerant	☐ Failed ☐ Suboptimal		
				☐ Contraindicated ☐ Intolerant	☐ Failed ☐ Suboptimal		
Are any of the above drugs still taken by th	e patient? No Yes – drug name((s):					
If yes, will it/they be discontinued? Yes							
Medication Examples Listed below are examples of the medication not be approved for bipolar I disorder or sch	ns used for bipolar I disorder and/or schize				elow may		
ABILIFY® (aripiprazole)	INVEGA® (paliperidone)	INVEGA® (paliperidone)		SEROQUEL® (quetiapine)			
CAPLYTA® (lumateperone)	LATUDA® (lurasidone)		ZYPREXA® (olanzapine)				
CLOZARIL® (clozapine)	REXULTI® (brexpiprazole)		Lithium				
FANAPT® (iloperidone)	RISPERDAL® (risperidone)		Divalproex/Valproic acid				
GEODON® (ziprasidone)	SAPHRIS® (asenapine)	SAPHRIS® (asenapine)			Carbamazepine		
Are there any risk factors that would preven No Yes - If yes, please list risk factor	, , , , , , , , , , , , , , , , , , ,						
Additional relevant information:							
This information is presented for information payment or coverage. Providers are encourage	al purposes only and is not intended to progred to contact third-party payers for spec	ovide reimbursement or lega	al advice. The info	ormation presented here	does not guarantee		

Reference: 1. 2024 ICD-10-CM. 2024 code tables, tabular and index. Centers for Medicare & Medicaid Services. Accessed September 13, 2024. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2025/

Please see Prescribing Information for AbbVie products, or visit https://www.rxabbvie.com/

